Arcturus Therapeutics’ (ARCT) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research note issued to investors on Thursday morning,Benzinga reports. The firm currently has a $60.00 price objective on the biotechnology company’s stock.

Several other equities research analysts have also commented on ARCT. Wells Fargo & Company reduced their price target on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Canaccord Genuity Group lowered their target price on Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating for the company in a report on Monday, March 10th. BTIG Research set a $48.00 price target on Arcturus Therapeutics and gave the company a “buy” rating in a report on Monday, March 10th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $59.20.

Arcturus Therapeutics Stock Performance

Shares of NASDAQ ARCT opened at $9.70 on Thursday. Arcturus Therapeutics has a 52-week low of $8.04 and a 52-week high of $45.00. The firm has a market capitalization of $263.06 million, a price-to-earnings ratio of -4.37 and a beta of 3.41. The stock has a 50 day moving average price of $13.89 and a 200 day moving average price of $16.89.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). The firm had revenue of $22.77 million for the quarter, compared to the consensus estimate of $44.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. Analysts forecast that Arcturus Therapeutics will post -2.22 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARCT. Hennion & Walsh Asset Management Inc. raised its stake in Arcturus Therapeutics by 21.0% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 99,254 shares of the biotechnology company’s stock valued at $1,051,000 after buying an additional 17,197 shares during the last quarter. Green Alpha Advisors LLC purchased a new position in shares of Arcturus Therapeutics in the 1st quarter valued at approximately $288,000. GAMMA Investing LLC boosted its stake in Arcturus Therapeutics by 3,482.9% in the 1st quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company’s stock worth $550,000 after purchasing an additional 5,085 shares in the last quarter. Woodline Partners LP grew its position in Arcturus Therapeutics by 3.5% during the 4th quarter. Woodline Partners LP now owns 806,912 shares of the biotechnology company’s stock worth $13,693,000 after purchasing an additional 26,956 shares during the last quarter. Finally, Two Sigma Investments LP increased its stake in Arcturus Therapeutics by 60.9% during the 4th quarter. Two Sigma Investments LP now owns 27,560 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 10,430 shares in the last quarter. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.